Several US states are dropping or considering dropping Medicaid coverage of GLP-1 weight-loss drugs, affecting thousands of patients. The move comes as demand for these drugs is rising, with some outlets suggesting a potential crisis in the healthcare system. It is unclear whether the loss of Medicaid coverage will lead to lower costs for the drugs or increased financial burdens on patients.